<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840762</url>
  </required_header>
  <id_info>
    <org_study_id>07-118</org_study_id>
    <nct_id>NCT00840762</nct_id>
  </id_info>
  <brief_title>A Comparison of Virco速TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication</brief_title>
  <official_title>A Randomized Comparison of Virco速TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruth M. Rothstein CORE Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virco</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruth M. Rothstein CORE Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to determine whether Virco速TYPE HIV-1 provides benefits equivalent to
      those provided by local expert review. The investigators propose that clinic patients of the
      Ruth M. Rothstein CORE Center who are having genotypic testing performed will be randomized
      in a 1:1 fashion to local expert review and to Virco速TYPE HIV-1. Results of either method
      will be shared with primary HIV care providers. Patient outcomes will be reviewed at a time
      point equal to or greater than 2 months and 6 months following the change in antiretroviral
      medications following the testing
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients having some documented genotypic HIV resistance but having more than one fully
      active medication will be randomized to either local review or algorithmic review by
      VircoType HIV-1.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with viral load &lt;1000 60days after HIV regimen change</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with viral load &lt;1000 180 days after HIV regimen change</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable viral load 60days after HIV regimen change</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with undetectable viral load 180days after HIV regimen change</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 Cell count change in each arm at 60 and 180 days</measure>
    <time_frame>60 and 180 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose regimen fails and who require repeat resistance testing at 180 and 360 days</measure>
    <time_frame>180 and 360 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of number of active drugs predicted by each review method and number of actual active drugs prescribed</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">756</enrollment>
  <condition>HIV-1</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>VircoType HIV-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotypic HIV resistance testing results interpreted by VircoType HIV-1 algorithm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local Expert review</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Local Expert HIV genotypic review, as per Badri, S. et al CID 2003</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>VircoType HIV-1 genotypic interpretation</intervention_name>
    <description>VircoType HIV-1 genotypic interpretation</description>
    <arm_group_label>VircoType HIV-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Local Expert Review of HIV Genotypic resistance testing</intervention_name>
    <description>Local Expert Review of HIV Genotypic resistance testing</description>
    <arm_group_label>Local Expert review</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV resistance testing that demonstrates resistance to at least one drug

          -  Patients of the CORE Center, Chicago Illinois

        Exclusion Criteria:

          -  Wild type HIV on resistance testing or less than or equal to one active antiretroviral
             medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruth M. Rothstein CORE Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David E Barker, MD</last_name>
    <phone>312-572-4503</phone>
    <email>dbarker@corecenter.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Kroc, MPH</last_name>
    <phone>312-572-4765</phone>
    <email>kkroc@corecenter.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Ruth M. Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David E Barker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harold A Kessler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheila M Badri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Blake Max, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen G Beavis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.rush.edu/rumc/page-1099611551068.html</url>
    <description>Rush Medical Center Section of Infectious Diseases</description>
  </link>
  <link>
    <url>http://www.uic.edu/pharmacy/about_the_college/index.php</url>
    <description>UIC College of Pharmacy</description>
  </link>
  <reference>
    <citation>Badri SM, Adeyemi OM, Max BE, Zagorski BM, Barker DE. How does expert advice impact genotypic resistance testing in clinical practice? Clin Infect Dis. 2003 Sep 1;37(5):708-13. Epub 2003 Aug 15.</citation>
    <PMID>12942405</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <last_update_submitted>January 25, 2010</last_update_submitted>
  <last_update_submitted_qc>January 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>David E. Barker, MD</name_title>
    <organization>The Ruth M. Rothstein CORE Center of Cook County</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV Genotypic testing</keyword>
  <keyword>resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

